# A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

> **NCT04086121** · PHASE2 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 14 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** Spesolimab

## Key facts

- **NCT ID:** NCT04086121
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-24
- **Primary completion:** 2021-04-28
- **Final completion:** 2022-02-23
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04086121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04086121, "A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04086121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*